REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI

被引：0
|
作者：
Baldi, Giacomo Giulio [1 ]
Vasile, Enrico [1 ]
Masi, Gianluca [1 ]
Loupakis, Fotios [1 ]
Stasi, Irene [1 ]
Salvatore, Lisa [1 ]
Fornaro, Lorenzo [1 ]
Cupini, Samanta [1 ]
Pfanner, Elisabetta [2 ]
Brunetti, Isa Maura [2 ]
Di Donato, Samantha [2 ]
Caponi, Sara [1 ]
Allegrini, Giacomo [3 ]
Antonuzzo, Andrea [1 ]
Ricci, Sergio [2 ]
Andreuccetti, Michele [1 ]
Falcone, Alfredo [1 ,4 ]
机构：
[1] Azienda Osped Univ Pisana, Dipartimento Int Oncol Med, Azienda USL Livorno 6, Ist Toscano Tumori, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med 1, Ist Toscano Tumori, Pisa, Italy
[3] Azienda USL 5, UO Oncol Med, Pontedera, PI, Italy
[4] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, I-56100 Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients
    Vasile, E.
    Vivaldi, C.
    Fornaro, L.
    Caparello, C.
    Musettini, G.
    Pasquini, G.
    Catanese, S.
    Lencioni, M.
    Ricci, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [42] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [43] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [44] Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer
    Sunakawa, Yu
    Schirripa, Marta
    Lenz, Heinz-Josef
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 117 - 126
  • [45] Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study)
    Deng, Yanhong
    Wang, Lei
    Liu, Guanjian
    Hu, Huabin
    Cai, Yue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
    Vivaldi, Caterina
    Caparello, Chiara
    Musettini, Gianna
    Pasquini, Giulia
    Catanese, Silvia
    Fornaro, Lorenzo
    Lencioni, Monica
    Falcone, Alfredo
    Vasile, Enrico
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) : 938 - 945
  • [47] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Spadi, Rosella
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17): : 1609 - 1618
  • [48] Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
    Marques, Rui Pedro
    Duarte, Goncalo S.
    Sterrantino, Carmelo
    Pais, Helena Luna
    Quintela, Antonio
    Martins, Ana Paula
    Costa, Joao
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 118 : 54 - 62
  • [49] First-line treatment options for patients with metastatic colorectal cancer
    Richard L Schilsky
    [J]. Nature Clinical Practice Oncology, 2004, 1 : 70 - 71
  • [50] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
12345